0001818382-26-000004
SEC filingHumacyte, Inc. reported its first full year of commercial operations in FY 2025 following the FDA approval of Symvess in December 2024. The company generated total revenue of $2.0 million, comprised of $1.4 million in product revenue from U.S. sales of Symvess for vascular trauma and $0.6 million in contract revenue. Operating expenses totaled $110.2 million, including $69.3 million in R&D and $31.2 million in G&A expenses, resulting in an operating loss of $108.1 million. Net loss improved significantly to $40.8 million from $148.7 million in FY 2024, primarily due to a $59.5 million non-cash gain from the change in fair value of the Contingent Earnout Liability and a $38.8 million gain from derivative fair value changes, partially offset by a $22.3 million loss on debt extinguishment. The company ended the year with $50.5 million in cash and cash equivalents and raised significant capital through equity offerings and a new term loan facility.
Humacyte achieved a significant milestone in FY 2025, transitioning to a commercial-stage company following the December 2024 FDA approval of Symvess for extremity vascular trauma. Total revenue reached $2.0 million, with $1.4 million from product sales and $0.6 million from contract revenue. Operating loss was $108.1 million, a 6% improvement from $114.4 million in FY 2024. Net loss improved substantially to $40.8 million from $148.7 million, primarily driven by non-cash gains of $59.5 million from the Contingent Earnout Liability remeasurement and $38.8 million from derivative fair value changes. The company terminated its Revenue Interest Purchase Agreement in December 2025, resulting in a $22.3 million loss on debt extinguishment.
Revenue in FY 2025 represents the company's first commercial sales following the U.S. launch of Symvess in Q1 2025. Product revenue of $1.4 million was generated from sales of Symvess for the vascular trauma indication. Contract revenue of $0.6 million was derived from a single contract to recover research and development expenses. The company is targeting additional indications including AV access for hemodialysis, with plans to submit a supplemental BLA in the second half of 2026. No geographic or product segment breakdown was disclosed beyond the total revenue figures.
Gross margin was negative due to cost of goods sold of $9.7 million against $2.0 million revenue, which included an $8.9 million inventory reserve adjustment. Operating margin was -5,305%, reflecting the early commercial stage with significant ongoing R&D investment of $69.3 million and G&A expenses of $31.2 million. R&D expenses decreased 22% YoY from $88.6 million as the company transitioned from late-stage clinical development. G&A expenses increased 21% YoY to $31.2 million, driven by commercial launch activities including sales force expansion. Stock-based compensation expense was $9.8 million.
Operating cash flow was -$105.0 million, compared to -$98.1 million in FY 2024. The company ended FY 2025 with $50.5 million in cash and cash equivalents and $0.2 million in restricted cash. Financing activities provided $61.5 million, including $39.8 million from a new Term Loan Facility and proceeds from equity offerings. The company raised approximately $103 million through public offerings and registered direct offerings during FY 2025. Total debt stood at $35.4 million under the new Term Loan Facility. Stockholders' equity was $3.1 million, with an accumulated deficit of $726.8 million.
Management acknowledged substantial doubt about the company's ability to continue as a going concern without additional capital. The company plans to seek additional funding through equity or debt financings. Strategic priorities include expanding Symvess commercialization, pursuing regulatory approval for AV access in hemodialysis, and advancing pipeline programs in PAD, CABG, and the BioVascular Pancreas for Type 1 diabetes. Key risks include the need for additional capital, market acceptance of Symvess, and successful completion of ongoing clinical trials.